Serum cytokeratin 19 fragment 21‐1 is a useful tumor marker for the assessment of extramammary Paget's disease

Abstract

Cytokeratin 19 fragment 21-1 (CYFRA 21-1) has been used as a tumor marker for several malignancies. However, to date, no studies have assessed whether CYFRA 21-1 could be a useful marker for extramammary Paget's disease (EMPD). The present study aimed to evaluate the significance of CYFRA 21-1 as a serum tumor marker for EMPD progression. Concentrations of serum CYFRA 21-1 and carcinoembryonic antigen (CEA) in 13 cases of EMPD were measured prior to undergoing treatment at Sapporo Medical University Hospital from January 2014 to May 2016. Four of the 13 patients had lymph node metastases at diagnosis, but none had distant metastases. Immunohistochemistry indicated that all 13 primary tumors and four metastatic tumors in lymph nodes were positive for cytokeratin 19. Although none of the 13 patients showed high serum CEA levels, six patients (46.2%) had elevated serum CYFRA 21-1. Furthermore, CYFRA 21-1 was reduced in association with post-treatment tumor reduction in all six patients. Among these six patients, four developed recurrence and metastasis during the follow-up period. CYFRA 21-1 was re-elevated in all four of these patients; however, serum CEA was elevated only in the patient with distant metastasis. These results suggest that CYFRA 21-1 is more sensitive compared with CEA, and can be useful as a tumor marker for evaluating tumor progression and treatment efficacy in patients with EMPD.

Serum cell‐free DNA levels are a useful marker for extramammary Paget disease

“…a). In particular, the elevated serum cfDNA levels in patients with localized EMPD are clinically important, because serum CYFRA and CEA levels were not increased in most patients with localized EMPD . In a confirmatory experiment, serum CYFRA levels in patients with localized EMPD were not elevated compared with those in healthy individuals, although the levels in patients with advanced EMPD were higher than those in both healthy individuals and patients with localized EMPD.…”

“…Extramammary Paget disease (EMPD) is generally characterized by a malignant skin tumour with good prognosis; however, the prognosis of metastatic EMPD is poor. Tumour markers of EMPD have been reported to be carcinoembryonic antigen (CEA) and cytokeratin 19 fragment (CYFRA), although serum CEA and CYFRA levels are not elevated in most patients with EMPD without metastasis. Therefore, further useful biomarkers are needed for the detection of EMPD, including early lesions, and for the evaluation of therapeutic efficacy.…”

Monitoring serum cytokeratin 19 fragment 21‐1 to determine the efficacy of docetaxel chemotherapy in advanced extramammary Paget's disease

“…1 Sweat glands, the luminal cells of the sweat duct and lower parts of the hair follicle are positive for CK19. 1 Sweat glands, the luminal cells of the sweat duct and lower parts of the hair follicle are positive for CK19.…”

“…1 A 65-year-old Japanese woman presented to our hospital with a 5-month history of bilateral leg edema and genital bleeding. However, invasive EMPD tumors cause metastases to the regional lymph nodes or other organs.…”

“…[1][2][3] In this study, we introduce our one-stage successful reconstruction of huge perineal keloids using bilateral modified Despite being infrequent, keystone flaps have been spotlighted by several surgeons due to their simplicity, versatility and reliability.…”